Eli Lilly (LLY) announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use has issued an opinion recommending donanemab for the treatment of early symptomatic Alzheimer’s disease in adults with confirmed amyloid pathology who are apolipoprotein E e4 heterozygotes or non-carriers. The European Commission is expected to make a regulatory decision on donanemab in the coming months.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LLY:
- Eli Lilly and Incyte’s Rheumatoid Arthritis Study: A Potential Market Game-Changer
- Eli Lilly’s LOXO-783 Study: A Potential Game-Changer in Cancer Treatment
- Eli Lilly’s Lebrikizumab Study: A Promising Step in Pediatric Dermatology
- Eli Lilly and Loxo Oncology’s Promising Phase 3 Study in CLL/SLL: A Potential Game-Changer?
- Eli Lilly’s LIBRETTO-432: A Promising Study in Lung Cancer Treatment